# Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

> **NCT03818061** · PHASE2 · COMPLETED · sponsor: **Centre Leon Berard** · enrollment: 33 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03818061
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-26
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03818061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03818061, "Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT03818061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*